Tevogen Bio Expands On Microsoft Partnership To Integrate Machine Learning And AI Into Preclinical Processes, Accelerating Drug Development And Reducing Costs; Says "Current Timeline For Drug Development Is 10-12 Years And Costs ~$1B-$3B. Approach Has The Potential To Shorten Timelines And Substantially Reduce Costs."
- Current timeline for drug development is 10-12 years and costs approximately $1-3 billion. Tevogen's approach has the potential to shorten timelines and substantially reduce costs.
- Tevogen's AI initiative, Tevogen.AI, will pursue two key objectives, applying machine learning to existing processes to accelerate drug development and lower costs, and using Microsoft's industry leading AI tools to develop proprietary algorithms designed to decode the relationship between genetics and T cells.
WARREN, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shares details of its partnership with Microsoft (NASDAQ:MSFT) for Startups.
Through this partnership Tevogen.AI aims to achieve two key objectives. The first objective is to apply the principles of machine learning to rapidly expand Tevogen's ExacTcell pre-clinical pipeline by performing key simulations based on the successful trial results of TVGN 489. This capability may allow Tevogen's research team to analyze large datasets across the genome, yielding faster and more accurate target identification. The second objective uses Microsoft's advanced AI tools to develop proprietary algorithms that decode the interactions between human leukocyte antigens (HLA) and T cells. This capability may expand Tevogen's understanding of immune responses and identify new therapeutic opportunities, especially in areas with limited existing data.
